Effects of low-dose doxycycline and bisphosphonate clodronate on alveolar bone loss and gingival levels of matrix metalloproteinase-9 and interleukin-1 β in rats with diabetes: A histomorphometric and immunohistochemical study

Journal of Periodontology

Volumn 83, Issue 9, 2012, Pages 1172-1182

  Özdemir, Selin P ^a   Kurtis, Bülent ^a   Tuter, Gülay ^a   Bozkurt, Şeyma ^a,b   Gültekin, Sibel Elif ^a   Sengüven, Burcu ^c   Watanabe, Keiko ^c   Aydin, Sevtap ^d  

^a GAZI UNIVERSITY   (Turkey)

^b ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Bisphosphonate; Cytokines; Diabetes mellitus; Doxycycline; Matrix metalloproteinases; Periodontium

Indexed keywords

ANTIINFECTIVE AGENT; BONE DENSITY CONSERVATION AGENT; CLODRONIC ACID; DOXYCYCLINE; GELATINASE B; INTERLEUKIN 1BETA; MMP9 PROTEIN, RAT; STREPTOZOCIN;

ALVEOLAR BONE LOSS; ANIMAL; ARTICLE; BIOPSY; CHEMISTRY; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; GINGIVA; IMMUNOLOGY; JAW; LYMPHOCYTE; MALE; PATHOLOGY; PERIODONTAL DISEASE; PERIODONTITIS; RAT; WISTAR RAT;

ALVEOLAR BONE LOSS; ALVEOLAR PROCESS; ANIMALS; ANTI-BACTERIAL AGENTS; BIOPSY; BONE DENSITY CONSERVATION AGENTS; CLODRONIC ACID; DIABETES MELLITUS, EXPERIMENTAL; DOXYCYCLINE; DRUG THERAPY, COMBINATION; GINGIVA; INTERLEUKIN-1BETA; LYMPHOCYTES; MALE; MATRIX METALLOPROTEINASE 9; PERIODONTITIS; RATS; RATS, WISTAR; STREPTOZOCIN; TOOTH MOBILITY;

EID: 84865963753     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2012.110459     Document Type: Article

References (62)

1. Mealey BL, Moritz AJ. Hormonal influences: Effects of diabetes mellitus and endogenous female sex steroid hormones on the periodontium. Periodontol 2000 2003; 32:59-81.
2. Mealey BL, Oates TW; American Academy of Periodontology. Diabetes mellitus and periodontal diseases. J Periodontol 2006;77:1289-1303.
3. Tsai C, Hayes C, Taylor GW. Glycemic control of type 2 diabetes and severe periodontal disease in the US adult population. Community Dent Oral Epidemiol 2002; 30:182-192.
4. Taylor GW, Burt BA, Becker MP, et al. Non-insulin dependent diabetes mellitus and alveolar bone loss progression over 2 years. J Periodontol 1998;69: 76-83.
5. Naguib G, Al-Mashat H, Desta T, Graves DT. Diabetes prolongs the inflammatory response to a bacterial stimulus through cytokine dysregulation. J Invest Dermatol 2004;123:87-92.
6. Lalla E, Lamster IB, Feit M, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Invest Dermatol 2000;105:1117-1124.
7. Duarte PM, de Oliveira MC, Tambeli CH, Parada CA, Casati MZ, Nociti FH Jr. Overexpression of interleukin1beta and interleukin-6 may play an important role in periodontal breakdown in type 2 diabetic patients. J Periodontal Res 2007;42:377-381.
8. Tatakis DN. Interleukin-1 and bone metabolism: A review. J Periodontol 1993;64(Suppl. 5):416-431.
9. Duarte PM, Neto JB, Casati MZ, Sallum EA, Nociti FH Jr. Diabetes modulates gene expression in the gingival tissues of patients with chronic periodontitis. Oral Dis 2007;13:594-599.
10. Salvi GE, Lang NP. Host response modulation in the management of periodontal diseases. J Clin Periodontol 2005;32(Suppl. 6):108-129.
11. Preshaw PM, Hefti AF, Jepsen S, Etienne D, Walker C, Bradshaw MH. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. J Clin Periodontol 2004;31:697-707.
12. Alencar VB, Bezerra MM, Lima V, et al. Disodium chlodronate prevents bone resorption in experimental periodontitis in rats. J Periodontol 2002;73:251-256.
13. Lee HM, Ciancio SG, Tüter G, Ryan ME, Komaroff E, Golub LM. Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug. J Periodontol 2004;75:453-463.
14. Newman MG, Takei HH, Carranza FA. Carranza's Clinical Periodontology, 10th ed. St. Louis: Elsevier; 2007: 813-825.
15. Silva JA, Lorencini M, Peroni LA, De La Hoz CL, Carvalho HF, Stach-Machado DR. The influence of type I diabetes mellitus on the expression and activity of gelatinases (matrix metalloproteinases-2 and-9) in induced periodontal disease. J Periodontal Res 2008;43:48-54.
16. Fleisch H. Bisphosphonates - History and experimental basis. Bone 1987;8(Suppl. 1):S23-S28.
17. Smith R, Russell RG, Bishop M. Diphosphonates and Page's disease of bone. Lancet 1971;1:945-947.
18. O'Doherty DP, Bickerstaff DR, McCloskey EV, et al. Treatment of Paget's disease of bone with amino-hydroxybutylidene bisphosphonate. J Bone Miner Res 1990;5:483-491.
19. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-79.
20. Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969; 165:1262-1264.
21. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. N Engl J Med 1991;88: 2095-2105.
22. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(Suppl. 12):2961-2978.
23. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-1021.
24. van Breukelen FJ, Bijvoet OL, Frijlink WB, Sleeboom HP, Mulder H, van Oosterom AT. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: Observations on regulation of serum calcium. Calcif Tissue Int 1982;34:321-327.
25. Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F. Renal failure associated with intravenous diphosphonates. Lancet 1983;1:471.
26. Fleisch H. Bisphosphonates: Mechanisms of action. Endocr Rev 1998;19:80-100.
27. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphospho-nates: Incidence and risk factors. J Clin Oncol 2005;23: 8580-8587.
28. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
29. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: Series of 10 cases. J Oral Pathol Med 2005;34:120-123.
30. Khamaisi M, Regev E, Yarom N, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2007;92:1172-1175.
31. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61: 1115-1117.
32. Hewitt C, Farah CS. Bisphosphonate-related osteo-necrosis of the jaws: A comprehensive review. J Oral Pathol Med 2007;36:319-328.
33. Crépin S, Laroche ML, Sarry B, Merle L. Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: Case report and literature review. Eur J Clin Pharmacol 2010;66:547-554.
34. Montazeri AH, Erskine JG, McQuaker IG. Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol 2007;79:69-71.
35. Van den Wyngaert T, Huizing MT, Vermorken JB. Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol 2007;19:315-322.
36. Llavaneras A, Golub LM, Rifkin BR, et al. CMT-8/clodronate combination therapy synergistically inhibits alveolar bone loss in LPS-induced periodontitis. Ann N Y Acad Sci 1999;878:671-674.
37. Ramamurthy N, Bain S, Liang CT, et al. A combination of subtherapeutic doses of chemically modified doxycycline (CMT-8) and a bisphosphonate (clodronate) inhibits bone loss in the ovariectomized rat: A dynamic histomorphometric and gene expression study. Curr Med Chem 2001;8:295-303.
38. Buduneli E, Vardar-Sengül S, Buduneli N, Atilla G, Wahlgren J, Sorsa T. Matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and laminin-5 gamma2 chain immunolocalization in gingival tissue of endotoxin-induced periodontitis in rats: Effects of low-dose doxycycline and alendronate. J Periodontol 2007;78:127-134.
39. Buduneli E, Vardar S, Buduneli N, et al. Effects of combined systemic administration of low-dose doxy-cycline and alendronate on endotoxin-induced peri-odontitis in rats. J Periodontol 2004;75:1516-1523.
40. Golub LM, Sorsa T, Lee HM, et al. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J Clin Periodontol 1995;22:100-109.
41. Caton JG, Ciancio SG, Blieden TM, et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol 2000;71:521-532.
42. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12:12-26.
43. Pontes Andersen CC, Buschard K, Flyvbjerg A, Stoltze K, Holmstrup P. Periodontitis deteriorates metabolic control in type 2 diabetic Goto-Kakizaki rats. J Periodontol 2006;77:350-356.
44. Graves DT, Naguib G, Lu H, Leone C, Hsue H, Krall E. Inflammation is more persistent in type 1 diabetic mice. J Dent Res 2005;84:324-328.
45. Doxey DL, Cutler CW, Iacopino AM. Diabetes prevents periodontitis-induced increases in gingival platelet derived growth factor-B and interleukin 1-beta in a rat model. J Periodontol 1998;69:113-119.
46. Pontes Andersen CC, Flyvbjerg A, Buschard K, Holmstrup P. Relationship between periodontitis and diabetes: Lessons from rodent studies. J Periodontol 2007;78:1264-1275.
47. Bezerra MM, Brito GA, Ribeiro RA, Rocha FA. Lowdose doxycycline prevents inflammatory bone resorption in rats. Braz J Med Biol Res 2002;35:613-616.
48. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991;2:297-321.
49. Ramamurthy NS, Rifkin BR, Greenwald RA, et al. Inhibition of matrix metalloproteinase-mediated peri-odontal bone loss in rats: A comparison of 6 chemically modified tetracyclines. J Periodontol 2002;73: 726-734.
50. Laurén L, Osterman T, Karhi T. Pharmacokinetics of clodronate after single intravenous, intramuscular and subcutaneous injections in rats. Pharmacol Toxicol 1991;69:365-368.
51. Watanabe K, Petro BJ, Shlimon AE, Unterman TG. Effect of periodontitis on insulin resistance and the onset of type 2 diabetes mellitus in Zucker diabetic fatty rats. J Periodontol 2008;79:1208-1216.
52. Hirshberg LM. Place of electroencephalograpic biofeedback for attention-deficit/hyperactivity disorder. Expert Rev Neurother 2007;7:315-319.
53. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84:489-497.
54. Grossi SG. Treatment of periodontal disease and control of diabetes: An assessment of the evidence and need for future research. Ann Periodontol 2001;6: 138-145.
55. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-1480.
56. Weinreb M, Quartuccio H, Seedor JG, et al. Histomor-phometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodontal Res 1994;29: 35-40.
57. Rocha M, Nava LE, Vázquez de la Torre C, Sánchez- Márin F, Garay-Sevilla ME, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: A randomized, placebo-controlled trial. J Periodontol 2001;72:204-209.
58. Yaffe A, Herman A, Bahar H, Binderman I. Combined local application of tetracycline and bisphosphonate reduces alveolar bone resorption in rats. J Periodontol 2003;74:1038-1042.
59. Karimbux NY, Ramamurthy NS, Golub LM, Nishimura I. The expression of collagen I and XII mRNAs in Porphyromonas gingivalis-induced periodontitis in rats: The effect of doxycycline and chemically modified tetracycline. J Periodontol 1998;69:34-40.
60. Deo V, Gupta S, Bhongade ML, Jaiswal R. Evaluation of subantimicrobial dose doxycycline as an adjunct to scaling and root planing in chronic periodontitis patients with diabetes: A randomized, placebo-controlled clinical trial. J Contemp Dent Pract 2010;11(3):009-016.
61. Ryan ME, Usman A, Ramamurthy NS, Golub LM, Greenwald RA. Excessive matrix metalloproteinase activity in diabetes: Inhibition by tetracycline analogues with zinc reactivity. Curr Med Chem 2001;8:305-316.
62. Goutoudi P, Diza E, Arvanitidou M. Effect of periodontal therapy on crevicular fluid interleukin-1beta and interleukin-10 levels in chronic periodontitis. J Dent 2004;32:511-520.